Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04320628 · ClinicalTrials.gov registry record · NA
Randomized Double-Blind Controlled Clinical Trial
A NA study, sponsored by SerenaGroup.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT04320628 is a NA study that has completed, run by SerenaGroup. The registered enrollment target is 25 participants.
The verdict
NCT04320628, a NA study, has completed, sponsored by SerenaGroup.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The study is a randomized double-blind controlled clinical trial designed to compare the ability of NaOCl to NSS in the reduction of bacterial burden in nonhealing acute and chronic wounds.
Interventions
- DEVICE AnaSept®
- OTHER NSS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-05-20 |
| Est. Completion | 2022-03-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04320628
The ClinicalTrials.gov registry entry for NCT04320628 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SerenaGroup, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AnaSept® is the first listed.
NCT04320628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04320628 about?
NCT04320628 is a clinical study titled "Randomized Double-Blind Controlled Clinical Trial". The study is a randomized double-blind controlled clinical trial designed to compare the ability of NaOCl to NSS in the reduction of bacterial burden in nonhealing acute and chronic wounds.
What is the current status of trial NCT04320628?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2020-05-20. Estimated completion is 2022-03-01.
What interventions are being tested in trial NCT04320628?
The interventions under investigation include: AnaSept® (DEVICE), NSS (OTHER).
Who is sponsoring clinical trial NCT04320628?
This trial is sponsored by SerenaGroup, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.